|
|
|
|
|
|
|
PEER-T0-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Lutetium-177 PSMA Radioligand Therapy for Advanced Prostate Cancer: Reviewing the Pivotal VISION and TheraP Trials |
Michael Morris, MD
Daniel George hosts Michael Morris to discuss pivotal studies influencing the use of Pluvicto (lutetium PSMA-617) in treating prostate cancer. The conversation begins with the VISION study, which led to Pluvicto's approval by demonstrating significant improvements in radiographic progression-free survival rPFS and OS for patients with PSMA-positive disease. |
|
|
|
|
|
|
|
|
|
|
| Patient Selection for Radioligand Therapy: Case Study Discussion |
Amir Iravani, MD, and Evan Yu, MD
Phillip Koo hosts a discussion on patient selection for radioligand therapy (RLT) in prostate cancer, featuring Amir Iravani and Evan Yu. The conversation delves into complex clinical decisions involving advanced prostate cancer management. |
|
|
|
|
|
|
|
|
|
|
| Operationalizing and Coordinating Lutetium-177 PSMA Treatment: Roles of a Multidisciplinary Prostate Cancer Team |
Kristen Davis, MHS, PA-C, and Sarah Yenser Wood, MSN, ANP-BC, AOCNP, RN
Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis, a Physician Assistant, and Sarah Wood, a Nurse Practitioner. |
|
|
|
|
|
|
|
|
|
|
| Efficacy and Toxicity of 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer in a Real-World Setting: Results from the U.S. Expanded Access Program and Comparison with Phase 3 VISION Data |
| Vishnu Murthy |
| Vishnu Murthy presented findings from the U.S. expanded access program evaluating the real-world efficacy and toxicity of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. These results were compared to those from the phase 3 VISION trial. The VISION trial demonstrated significant survival benefits with 177Lu-PSMA-617, leading to its approval for mCRPC treatment. |
|
|
|
|
|
| Patient Selection for Radioligand Therapy: How to Do It in Clinical Practice and How to Decide on the Number of Cycles
|
| Thomas Hope, MD
|
| Thomas Hope discusses patient selection for PSMA radioligand therapy in prostate cancer, focusing on imaging criteria and response monitoring. Trials like VISION and TheraP showed that patients with high PSMA uptake (SUVmean ≥10) responded better to therapy, while FDG PET may only be necessary in complex cases. Post-treatment SPECT imaging combined with PSA kinetics can guide decisions on treatment continuation, pauses, or changes.
|
|
|
|
|
|
|
|
|
|
|
| Prognostic Value of Post-Therapy SPECT/CT Imaging in Patients Undergoing 177Lu-PSMA-617 Radioligand Therapy: Results from 3 Clinical Trials |
| Raghava K. Karri, MD |
| Raghava Karri presents findings from a retrospective analysis of post-therapy SPECT/CT imaging in patients undergoing 177Lu-PSMA-617 radioligand therapy across three clinical trials. The study found that volumetric parameters, such as molecular tumor volume and total lesion activity, were prognostic for overall survival in univariate analysis, though new lesions on post-therapy SPECT/CT were more strongly prognostic in both univariate and multivariate analyses. |
|
|
|
|
|
| Combination Treatment of Prostate Cancer Using Pembrolizumab with PSMA Based Radioligands
|
| Thomas Hope, MD
|
| Thomas Hope presents findings on the combination of Pembrolizumab with PSMA-based radioligands for treating prostate cancer, highlighting its potential to enhance immune response by targeting immune checkpoints. Two trials, the PRINCE trial and the UCSF study, showed promising results in metastatic castration-resistant prostate cancer, with the UCSF trial utilizing a single priming dose of 177Lu-PSMA-617 to minimize toxicity while optimizing treatment efficacy.
|
|
|
|
|
|
| PSMA Radioligand Therapy – State of the Art |
| Ken Herrmann, MD |
| Ken Herrmann presents advances in PSMA radioligand therapy for prostate cancer, highlighting the success of 177Lu-PSMA-617 in pivotal trials like VISION and TheraP, which demonstrated significant improvements in progression-free and overall survival for mCRPC patients. Ongoing research aims to expand its use into earlier treatment lines and explore new therapeutic targets, such as human Kallikrein 2 and gastrin-releasing receptors, to address unmet clinical needs in prostate cancer care. |
|
|
|
|
|
|
|
|
|
|
